Shantha Biotechnics Ltd was founded by Dr KI Varaprasad, an electronics engineer by profession, in 1993. Realising the need for an affordable Hepatitis-B vaccine for India, he decided to develop the technology in-house rather than importing it at a higher cost.
The project began modestly as a research and development (R&D) outfit at the Osmania University under the industry–university interactive programme in 1993 and later at the Centre for Cellular and Molecular Biology (CCMB), until an independent R&D facility was built.
In 1997, Shantha developed and commercialised India's first r-DNA Hepatitis-B vaccine. In July 2001, Shanvac -b was prequalified by World Health Organisation (WHO) and has since been supplied to UN agencies such as UNICEF and PAHO.
Merieux Alliance group, based in France, acquired majority stake in Shantha Biotechnics Limited (Shantha) in November, 2006. In July, 2009, the company was acquired by Sanofi, which is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions.
Today, Shantha is a fully integrated biotechnology company involved in R&D, manufacturing and marketing.
Shantha Biotech: Single Focus, Billion Smiles
|2014||Shantha’s Pentavalent Pediatric Vaccine is prequalified by WHO.|
|2006||Merieux Alliance group, based in France, acquires majority stake in Shantha Biotechnics Limited.|
|2005||Founder Dr Varaprasad Reddy receives Padma Bhushan for his efforts in developing an affordable vaccine against Hepatitis-B through totally indigenous efforts and thereby creating the biotech revolution in India.|
|1997||Shanta develops India’s first r-DNA Hepatitis-B vaccine.|
|1993||Shantha Biotechnics Ltd is established.|
Updated: June, 2014